huahaipharm(SH:600521)2014-04-27 16:00Financial Performance - Net profit attributable to shareholders decreased by 48.28% to CNY 52,456,217.49 year-on-year[12] - Operating revenue declined by 12.20% to CNY 522,674,027.66 compared to the same period last year[12] - The company reported a significant decrease in net profit after deducting non-recurring gains and losses, down 54.67% to CNY 46,325,399.39[12] - The company's net profit for the first quarter of 2014 was ¥54,118,819.78, a decrease of 47.25% compared to ¥102,596,472.80 in the same period last year[16] - Net profit for Q1 2014 was CNY 54.12 million, a decline of 47.36% compared to CNY 102.60 million in Q1 2013[30] - Net profit for Q1 2014 was CNY 40.07 million, down 40.5% from CNY 67.37 million in the same period last year[33] - The company reported a total comprehensive income of CNY 54.42 million for Q1 2014, compared to CNY 102.53 million in Q1 2013, indicating a significant decline[30] - The total comprehensive income for Q1 2014 was CNY 40.07 million, reflecting a decrease of 40.5% compared to CNY 67.37 million in Q1 2013[33] Assets and Liabilities - Total assets increased by 5.39% to CNY 4,707,005,946.16 compared to the end of the previous year[12] - Total assets increased to ¥4,707,005,946.16, up from ¥4,466,104,075.41, reflecting a growth of 5.4%[23] - Total liabilities increased to CNY 1.63 billion from CNY 1.45 billion at the beginning of the year, reflecting a rise of 12.93%[24] - The company's total equity increased to CNY 3.07 billion from CNY 3.02 billion at the beginning of the year, reflecting a growth of 1.93%[24] Cash Flow - Net cash flow from operating activities dropped by 71.12% to CNY 23,076,584.78[12] - Cash flow from operating activities generated a net amount of CNY 23.08 million, significantly lower than CNY 79.90 million in Q1 2013, reflecting a decline of 71.1%[35] - Cash inflow from financing activities was CNY 544.86 million in Q1 2014, an increase of 23.5% from CNY 440.66 million in Q1 2013[37] - Investment activities resulted in a net cash outflow of CNY 140.87 million in Q1 2014, compared to a net outflow of CNY 102.72 million in Q1 2013[37] Shareholder Information - The number of shareholders reached 36,833 at the end of the reporting period[13] - The largest shareholder, Chen Baohua, holds 26.64% of the shares, totaling 209,188,726 shares[13] Expenses and Costs - The company's sales expenses increased by 96.72% to ¥45,296,320.86, attributed to enhanced marketing efforts for formulation products[16] - Sales expenses increased to CNY 18.03 million, up 75.7% from CNY 10.25 million in Q1 2013, indicating higher costs associated with sales efforts[33] Other Financial Metrics - Basic earnings per share decreased by 46.15% to CNY 0.07[12] - Basic earnings per share for Q1 2014 were CNY 0.07, down from CNY 0.13 in the same period last year[30] - The weighted average return on net assets fell by 3.36 percentage points to 1.73%[12] - The company's short-term borrowings rose by 57.83% to ¥820,509,708.35, driven by increased working capital needs[16] - Investment income surged by 1210.10% to ¥13,209,873.97, primarily due to increased interest from entrusted loans and financial products[16] - The fair value change loss was reported at -¥4,767,297.70, a significant decline of 149.78% compared to the previous year[16] - Long-term prepaid expenses reached ¥8,501,296.51, marking a 100% increase due to improvements on leased fixed assets[16] - The company's receivables increased by 30.98% to ¥12,837,153.63, reflecting a higher volume of transactions settled via notes[16] - The company's tax payable decreased by 35.46% to ¥55,897,373.90, resulting from increased tax payments during the period[16]